Abstracts tagged "Myopathies"

Abstract Number: 1088 • ACR Convergence 2020
Recruitment Rates of Virtual Remote Research (Tele-Research) in Myositis
Siamak Moghadam-Kia¹, Chester Oddis², Swamy Venturupalli³, Shalini Mahajan⁴, Daphne Scaramangas Plumley⁵, Dana Ascherman⁶, Nicole Neiman⁷, Faith Onelangsy⁷, Diane Koontz¹, Kim Goldby-Reffner⁷, Sedin Dzanco⁷, Lei Zhu⁶ and Rohit Aggarwal⁶, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Cedars Sinai Medical Center, Los Angeles, ⁴Attune Health, Los Angeles, ⁵Attune Health, Los Angeles, CA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷UPMC, Pittsburgh
Background/Purpose: There is a paucity of randomized, controlled clinical trials in myositis. Subject enrollment and retention in clinical trials for this rare, heterogeneous disease has…
Abstract Number: 0933 • ACR Convergence 2020
Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis
Julie Paik¹, Fredrick Wigley², Laura Fayad³, Laura Hummers⁴ and Michael Jacobs¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Joh, Baltimore, MD, ⁴Johns Hopkins Univerisity, Ellicott City, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is underappreciated yet an important manifestation of SSc. While it has been reported that there are distinct histopathologic…
Abstract Number: 1096 • ACR Convergence 2020
Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
Jammie Law¹, Ana Valle², Katherine Mullins³ and Shereen Mahmood⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…
Abstract Number: 0958 • ACR Convergence 2020
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
Rohit Aggarwal¹, Howard Rockette², Swamy Venturupalli³, Galina Marder⁴, Mazen Dimachkie⁵, David Gazeley⁶, Floranne C. Ernste⁷, Leslie Crofford⁸, Siamak Moghadam-Kia⁹, Diane Koontz⁹, Lei Zhu¹ and Chester Oddis¹⁰, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Cedars Sinai Medical Center, Los Angeles, ⁴Northwell, New York, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷Mayo Clinic, Rochester, ⁸Vanderbilt University Medical Center, Nashville, ⁹University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To assess the efficacy and tolerability of tocilizumab (anti-IL-6R, TCZ), in a multi-center, randomized, double blind, placebo-controlled trial in refractory adult dermatomyositis (DM) and…
Abstract Number: 1097 • ACR Convergence 2020
Immunophenotypic Characterization of Myeloid Derived Supressor Cells (MDSCs) and Their Relationship to the Clinical Characteristics of Patients with Inflammatory Myopathies
Hector Culebro¹, Jose Torres-Ruiz², Fabiola Cassiano Quezada¹ and Alfredo Perez Fragoso¹, ¹INCMNSZ, MEXICO, Mexico, ²NIAMS, National Institute of Health, Bethesda
Background/Purpose: Myeloid derived suppressor cells (MDSCs) including their granulocyte (Gr-MDSCs) and monocyte (Mo-MDSCs) subtypes constitute a cellular subset with potent immune regulatory capacity. An augmented…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].